Lv4
420 积分 2021-07-15 加入
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy
2个月前
已完结
CAR T-cell Therapy for Central Nervous System Lymphoma
2个月前
已完结
Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies
3个月前
已完结
The role of MRD monitoring and options for CLL management in relapsed/refractory disease
3个月前
已关闭
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
3个月前
已完结
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
4个月前
已完结
Advances in the treatment of mantle cell lymphoma with BTK inhibitors
5个月前
已完结
Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one?
5个月前
已完结
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond
5个月前
已完结
Challenges of treating mantle cell lymphoma in older adults
5个月前
已完结
皖公网安备34019202002308
